Company
Syrna Therapeutics
Silencing disease-causing proteins by covalently modifying their mRNA
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Our small-molecule inhibitors selectively target and modify unique binding sites in the mRNA of disease-causing proteins to prevent expression by blocking the ribosome.
Funding snapshot
- Total raised
- $10.9MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $10.9M2023-08-02
Funding rounds
- Round, 2023
- $10.9M2023-08-02, SEC form D sold, 3 investors
Loading relationship preview